Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
Neuropathology of white matter disease in Leber's hereditary optic neuropathy.
Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™
Phase 3 Study of RPC1063 in Relapsing MS
Daclizumab Therapy for Multiple Sclerosis.
TGFβ Signaling Regulates the Timing of CNS Myelination by Modulating Oligodendrocyte Progenitor Cell Cycle Exit through SMAD3/4/FoxO1/Sp1.
UCSF Neuroimmunology Seminar
Mechanical environment modulates biological properties of oligodendrocyte progenitor cells.
BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) (INSPIRE)
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.
Alerting Network Dysfunction in Early Multiple Sclerosis.
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats.
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis.
The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain.
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Pharmacokinetics of CAMPATH-1H in BMT patients.
Multiple sclerosis immunology: The healthy immune system vs the MS immune system.
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL.
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration.
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.

Pages